Introduction {#s1}
============

Dopamine (DA)-releasing neurons in the mammalian midbrain play an important role in fundamental behaviors, including motivation, reinforcement learning and motor control, and their dysfunction is associated with a wide range of neuropsychiatric disorders ([@bib91]; [@bib22]; [@bib73]; [@bib61]; [@bib67]). The major target of midbrain DA neurons is the striatum, a large subcortical structure implicated in the selection and reinforcement of motor actions. DA neurons located in the substantia nigra pars compacta (SNc) project mainly to the dorsal striatum (also known as the caudate and putamen, CPu), whereas those in the ventral tegmental area (VTA) innervate the ventral striatum (or nucleus accumbens, NAc), forming the nigrostriatal and mesolimbic pathways, respectively. The striatum controls motor behavior through two parallel output streams with opposing effects; the so-called 'direct' and 'indirect' pathways. Each pathway arises from distinct groups of GABAergic striatal projection neurons (SPNs) that differ, amongst other things, in their response to DA ([@bib28]; [@bib86]). By providing DA to the striatum, SNc and VTA neurons are believed to play a pivotal role in balancing the activity of direct- and indirect-pathway SPNs. However, our understanding of the cellular and molecular mechanisms employed by DA neurons to modulate striatal function remains incomplete.

Although the activation of metabotropic receptors following the release of DA from SNc/VTA neurons is undoubtedly central to their function, DA neurons also co-release several other transmitters that shape striatal output ([@bib36]; [@bib78]; [@bib82]; [@bib85]). In particular, we recently showed that DA neurons in SNc potently inhibit action potential firing in SPNs by releasing a transmitter that activates GABA~A~ receptors ([@bib85]). Release of this neurotransmitter requires activity of the vesicular monoamine transporter Slc18a2 (VMAT2), which can be replaced by exogenous expression of the vesicular GABA transporter Slc32a1 (also known as VGAT or VIAAT). In addition, VMAT2 expression in SPNs lacking VGAT is sufficient to sustain GABAergic transmission. Collectively, these findings suggest that SNc neurons co-release GABA using VMAT2 for vesicular loading. However, this study raises several important questions. First, does GABAergic transmission generalize to DA neurons in the VTA, or is it limited to nigrostriatal afferents? Second, what is the identity of the transmitter released by DA neurons? GABA exists as a zwitterion at neutral pH and lacks the characteristic molecular structure of VMAT2 substrates, which typically feature an aromatic ring and a positive charge ([@bib94]). GABA~A~ receptors can be activated by several naturally-occurring agonists and allosteric modulators, including β-alanine, taurine, imidazole-4-acetic acid and neurosteroids ([@bib42]; [@bib9]). Although none of these molecules constitute ideal candidates for VMAT2-dependent vesicular transport based on their structure, charge, or both, they nonetheless raise the possibility that DA neurons liberate a transmitter other than GABA to inhibit SPNs. Third, do all DA neurons contribute to GABAergic signaling, or is it reserved to a subpopulation of cells, similar to glutamate co-release from DA neurons ([@bib37]). Finally, how is inhibitory synaptic transmission sustained in DA neurons? Addressing this point will help identify molecules required for GABAergic transmission by DA neurons and will permit the development of genetic tools to determine the relative contribution of SPN inhibition by DA neurons in vivo under normal and pathological conditions.

In this study, we address these questions by examining the cellular and molecular mechanisms that underlie the rapid GABA~A~ receptor-mediated inhibition of SPNs upon stimulation of DA axons. Our results provide strong evidence that the inhibitory transmitter released by midbrain DA neurons is GABA, and suggest that GABA co-release is a general feature of all midbrain DA neurons. Moreover, we reveal that DA neurons rely on GABA uptake through the plasma membrane---but not on de novo GABA synthesis---to sustain GABAergic transmission.

Results {#s2}
=======

Stimulation of mesolimbic axons evokes inhibitory currents in striatal projection neurons {#s2-1}
-----------------------------------------------------------------------------------------

We recently reported that activation of SNc axons in dorsal striatum evokes monosynaptic, GABA~A~ receptor-mediated inhibitory postsynaptic currents (IPSCs) in SPNs ([@bib85]; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). To determine whether this GABAergic signaling extends to DA neurons projecting to ventral striatum, we expressed channelrhodopsin 2 (ChR2) in the VTA using one of two approaches ('Materials and methods'). We either injected *Slc6a3-ires-Cre* mice ([@bib6]) stereotaxically with an adeno-associated virus expressing Cre recombinase-dependent ChR2 ([Figure 1A](#fig1){ref-type="fig"}) or drove ChR2 expression genetically by crossing *Slc6a3-ires-Cre* mice to transgenic mice ([@bib55]) containing a conditional allele of ChR2 in the *Rosa26* locus ([Figure 1D](#fig1){ref-type="fig"}). Mice also harbored *Drd2-Egfp* or *Drd1a-tdTomato* bacterial artificial chromosome (BAC) transgenes to permit distinction between direct- and indirect-pathway SPNs, respectively ([@bib32]; [@bib2]). We performed whole-cell voltage-clamp recordings from SPNs in sagittal brain slices of NAc in the presence of inhibitors of ionotropic glutamate receptors (NBQX and R-CPP) and metabotropic GABA~B~ receptors (CGP55845) to prevent excitatory synaptic transmission by dopaminergic axons, as well as modulatory effects of GABA~B~ receptors, respectively. Under our recording conditions, optogenetic stimulation of VTA axons with brief (1 ms) flashes of blue light reliably evoked inward IPSCs in direct- and indirect-pathway SPNs that were blocked by the GABA~A~ receptor antagonists picrotoxin (n = 12; [Figure 1B,E](#fig1){ref-type="fig"}) and SR95531 (n = 4, not shown). With the exception of synaptic latency, optogenetically-evoked IPSCs (oIPSCs) exhibited similar properties in both experimental systems and were consequently pooled for analysis. They averaged 353 ± 60 pA in peak amplitude (range = 68--905 pA; n = 16) and their kinetics were similar to those observed in dorsal striatum ([@bib85]; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), with a 10--90% rise time of 2.4 ± 0.2 ms and a decay time constant of 46.8 ± 7.2 ms. The synaptic latency of oIPSCs in NAc did not differ from that observed in dorsal striatum under similar experimental conditions ([Figure 1C,F](#fig1){ref-type="fig"}), indicating that the connection is monosynaptic. Synaptic stimulation of midbrain DA neurons therefore directly engages GABA~A~ receptors on SPNs in both dorsal and ventral striatum.10.7554/eLife.01936.003Figure 1.Stimulation of VTA axons evokes GABAergic currents in nucleus accumbens SPNs.ChR2 was expressed in VTA DA neurons virally (**A**--**C**) or genetically (**D**--**F**). (**A**) Coronal cross section of a *Slc6a3-ires-Cre* mouse ventral midbrain immunolabeled for TH (red) showing viral transduction of ChR2-EYFP in the VTA (green). (**B**) Representative oIPSC recorded from an indirect-pathway SPN in NAc before (black trace) and after (gray trace) bath application of the GABA~A~ receptor antagonist picrotoxin (100 μM). Blue line depicts a 1-ms full field flash of 473 nm laser light (5 mW·mm^−2^). All recordings in this and subsequent figures were performed at −70 mV using a high Cl^−^internal solution in the presence of NBQX (10 μM), R-CPP (10 μM), and CGP55845 (2--5 μM) in the perfusate. (**C**) Latency from flash onset to oIPSC onset in NAc and dorsal striatum (Caudate/Putamen, CPu) SPNs. For analysis of oIPSCs in CPu, ChR2 was expressed in SNc in a separate cohort of mice. White circles depict individual recordings, red circles are mean ± SEM. (**D**--**F**) As in (**A**--**C**) for recordings in *Slc6a3-ires-Cre*;Ai32 mice. Note that the synaptic latency in these mice is significantly longer than in virally transduced *Slc6a3-ires-Cre* mice in both CPu and NAc (p\<0.001, Mann--Whitney test), presumably because of lower ChR2 expression in Ai32 mice.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.003](10.7554/eLife.01936.003)10.7554/eLife.01936.004Figure 1---figure supplement 1.Properties of DA neuron oIPSCs in dorsal striatum.ChR2 was expressed in SNc DA neurons virally. (**A**) or genetically (**B**). (**A**) Overlay of fifteen consecutive light-evoked (1ms, 473 nm, 5 mW·mm^−2^; blue line) IPSCs recorded under control conditions at −70 mV from a SPN in the dorsal striatum of a *Slc6a3-ires-Cre* mouse previously injected in the SNc with an AAV encoding Cre-dependent ChR2-mCherry. The first trace obtained after break-in is in black and subsequent oIPSCs are shown in progressively lighter shades of gray. The magenta trace depicts the average waveform of the first five oIPSCs. Recordings were performed with NBQX (10 μM), R-CPP (10 μM), and CGP55845 (2 μM) in the perfusate. (**B**) As in (**A**) for a SPN recorded under control conditions in the dorsal striatum of a *Slc6a3-ires-Cre*;Ai32 mouse. (**C**) Plot of the amplitude of consecutive oIPSCs shown in (**A**; magenta) and (**B**; green) over time. (**D**) As in (**C**) for oIPSCs recorded in dorsal striatum SPNs from AAV-infected mice (n = 17; magenta), Ai32 mice (n = 8; green), or both (n = 25, black). Amplitude is normalized to the first oIPSC after break-in. Note how the amplitude of oIPSCs progressively decreases with each stimulus under control conditions, regardless of the method used for expressing ChR2. This decrement in oIPSC amplitude is specific to dopaminergic synapses, as oIPSCs recorded from the collaterals of iSPNs in *Adora2a-Cre* expressing ChR2-mCherry in the dorsal striatum remained maintained their amplitude for the duration of the recording (n = 8; gray). Data represent mean ± SEM. \*p\<0.001 vs black trace; Sidak\'s multiple comparison test. (**E**) Mean latency from flash onset to oIPSC onset in individual dorsal striatum SPNs recordings from AAV-infected (magenta) and Ai32 (green) mice. The difference in synaptic delay are likely due to differences in expression levels of ChR2. Mean (±SEM) shown in red. \*p\<0.001, Mann--Whitney test. (**F**) Mean standard deviation (SD) of the synaptic latency of oIPSCs in individual cells indicates little temporal jitter in both experimental models, in agreement with monosynaptic transmission. Mean (±SEM) shown in red. n.s., no significant difference between means (p=0.8; Mann--Whitney test). (**G**) Time course of oIPSC amplitude rundown starting at the time of drug application (or the 5^th^ stimulus for control recordings in ACSF). The number of SPN recordings in each condition are: ACSF, 25; picrotoxin, 19; SR95531, 11; SKF 89976A, 9; SKF 89976A+SNAP-5114, 8. Changes in the decay kinetics of oIPSCs shown in [Figure 2](#fig2){ref-type="fig"} were quantified 3--4 min after initiating the perfusion of SKF89976A, just as the effects of the GABA~A~ receptor antagonists begin to significantly inhibit oIPSCs. Note that acute application of GAT antagonists does not immediately affect the amplitude of oIPSCs in SPNs. Data represent mean ± SEM. \*p\<0.01, picrotoxin or SR95531 vs black trace; Tukey\'s multiple comparison test.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.004](10.7554/eLife.01936.004)

Dopaminergic IPSCs are shaped by membrane GABA transporters {#s2-2}
-----------------------------------------------------------

The chemical identity of a synaptic neurotransmitter is traditionally established by determining whether a synapse fulfills several necessary criteria. They include the presence of (1) presynaptic synthetic enzymes, (2) presynaptic vesicular transporters, (3) postsynaptic receptors, and (4) a biochemical mechanism for inactivation. In the case of GABAergic signaling at dopaminergic synapses, conditions 2 and 3 are respectively satisfied by the presence of VMAT2 in DA neurons and GABA~A~ receptors in SPNs. For many central nervous system transmitters, condition 4 is mediated by diffusion and reuptake through plasma membrane transporters. Of the four genes identified in mice that encode high affinity membrane GABA transporters, *Slc6a1* is expressed predominantly throughout the brain ([@bib13]; [@bib52]). Its gene product, mGAT1, distributes mainly to presynaptic terminals of GABAergic neurons and serves to shape the amplitude and time course of IPSCs as well as regulate extrasynaptic levels of GABA ([@bib38]; [@bib41]; [@bib64]; [@bib21]; [@bib19]; [@bib15]; [@bib47]; [@bib18]). Importantly, mGAT1 is highly selective for GABA and does not transport structurally similar GABA~A~ receptor agonists such as β-alanine, taurine, and muscimol ([@bib43]; [@bib80]). Thus, we reasoned that if dopaminergic IPSCs are modulated by inhibition of mGAT1, it would provide compelling evidence that GABA is the neurotransmitter released.

To test this, we recorded dopaminergic oIPSCs from SPNs in dorsal striatum ([Figure 2](#fig2){ref-type="fig"}). Stimulation intensity was calibrated to evoke sub-maximal IPSCs (approximately 20% of IPSC peak amplitude at maximum intensity; mean: 232 ± 40 pA, n = 19) in order to minimize spillover of GABA at dopaminergic synapses ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We compared the amplitude and kinetics of IPSCs recorded before (baseline) and during the first 3--4 min following bath application of control saline (ACSF; n = 9; [Figure 2A](#fig2){ref-type="fig"}) or saline containing SKF 89976A, a selective mGAT1 antagonist (n = 10; [Figure 2B](#fig2){ref-type="fig"}). In both conditions, the IPSC amplitude progressively declined to ∼70% of baseline (p\<0.01 each, Wilcoxon signed-rank test; [Figure 2C](#fig2){ref-type="fig"}), whereas the synaptic latency and 10--90% rise time remained unchanged relative to baseline (p\>0.1, Wilcoxon signed-rank test). The decrease in amplitude is consistent with previous reports of activity-dependent rundown of GABA and DA release from midbrain DA neurons in vitro ([@bib72]; [@bib85]; [@bib39]) and did not differ between conditions (p=0.8, Mann--Whitney test; [Figure 2C](#fig2){ref-type="fig"}, [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}), indicating that acute inhibition of mGAT1 does not interfere with neurotransmitter release or postsynaptic GABA~A~ receptors. By contrast, mGAT1 antagonism significantly affected decay kinetics: whereas oIPSC decay time constants remained stable in control recordings (baseline: 33.6 ± 5.8 ms; 3--4 min after ACSF wash-in: 32.1 ± 5.8 ms; p=0.6, Wilcoxon signed-rank test), they were prolonged by a factor of 3 in the presence of SKF 89976A (baseline: 38.6 ± 6.0 ms; 3--4 min after SKF 89976A wash-in: 115.9 ± 26.3 ms; p=0.002, Wilcoxon signed-rank test; [Figure 2D](#fig2){ref-type="fig"}). These results indicate that mGAT1 activity normally shortens the duration of dopaminergic IPSCs, likely by clearing released neurotransmitter from the extracellular space.10.7554/eLife.01936.005Figure 2.The decay kinetics of dopaminergic IPSCs are shaped by membrane GABA transporters.(**A**) Two representative oIPSCs recorded in SPNs using sub-maximal ChR2 stimulation (1ms; 0.3--2 mW·mm^−2^; blue line) before (baseline, left black trace) and 3--4 min after (middle gray trace) bath application of control saline (ACSF). *Right*, overlay of peak-normalized oIPSCs showing identical decay kinetics. (**B**) As in (**A**) for oIPSCs recorded in SKF 89976A (10 μM, in green). (**C**) Histogram of mean (±SEM) peak oIPSC amplitude normalized to baseline for SPNs perfused in ACSF (gray) and SKF 89976A (green). Number of recordings indicated in parentheses. (**D**) Plot of individual oIPSC decay time constants before and after bath application of ACSF and SKF 89976A. Mean (±SEM) shown in red. \*p=0.002 vs baseline, Wilcoxon signed-rank test.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.005](10.7554/eLife.01936.005)10.7554/eLife.01936.006Figure 2---figure supplement 1.oIPSC decay time constant increases with stimulus strength.(**A**) The decay time constant of oIPSCs evoked with maximal light intensity (5 mW·mm^−2^) does not correlate with oIPSC peak amplitude (n = 25 SPNs; R^2^ = 0.01, linear regression; red line). (**B**--**C**) In a subset of SPN recordings (n = 6), the amplitude (**B**) and decay time constant (**C**) of oIPSCs were measured at different light power densities (blue: 5 mW·mm^−2^; gray: 0.3 mW·mm^−2^). Maximal stimulation strength increased the mean amplitude and mean decay time constant of oIPSCs (red circles; p\<0.04 for both, Wilcoxon signed-rank test), suggesting that the ability of GATs to limit pooling and/or spillover of GABA at dopaminergic synapses is compromised at high light stimulation intensities.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.006](10.7554/eLife.01936.006)10.7554/eLife.01936.007Figure 2---figure supplement 2.mGAT1 controls ambient levels of GABA in the striatum.(**A**) Continuous whole-cell voltage-clamp recording (*V*~hold~ = −70 mV) from a direct pathway SPN (dSPN) upon bath application of the GABA~A~ receptor antagonist picrotoxin (100 μM, black bar) in the presence of NBQX (10 μM), R-CPP (10 μM), and CGP55845 (5 μM). Downward deflections represent spontaneous IPSCs. The presence of a standing inward current mediated by extracellular GABA is revealed upon application of picrotoxin, which evokes a shift in baseline holding current. (**B**) As in (**A**) for an indirect pathway SPN (iSPN) upon bath application of SKF 89976A (10 μM) and picrotoxin (indicated by green and black bars, respectively). Green box indicates the 3--4 min window following the onset of SKF 89976A perfusion during which oIPSCs, eIPSCs, sIPSCs and SKF 89976A-evoked currents are quantified. (**C**) Histogram of picrotoxin-evoked shift in holding current recorded in dSPNs under control conditions (ACSF, gray) or upon acute inhibition of mGAT1 (SKF 89976A, green). Number of recordings is indicated in parentheses. \*p\<0.01, Mann--Whitney test. (**D**) As in (**C**) for iSPNs. Note that no differences in tonic GABA~A~-receptor-mediated currents were observed between iSPNs and dSPNs, either in ACSF or SKF 89976A.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.007](10.7554/eLife.01936.007)

In the striatum, mGAT1 controls ambient levels of GABA that evoke a tonic GABA~A~ receptor-mediated conductance in SPNs ([@bib1]; [@bib47]; [@bib71]; [@bib18]). Consistent with this, acute pharmacological inhibition of mGAT1 was accompanied by a significant increase in holding current caused by a threefold increase in tonic GABA current in both direct- and indirect-pathway SPNs ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). To exclude the possibility that the increase in oIPSC decay time constant stems from changes in recording conditions during bath application of SKF 89976A, we also monitored spontaneous (s) IPSCs as well as IPSCs evoked electrically within the striatum (eIPSCs; [Figure 3](#fig3){ref-type="fig"}). Unlike dopaminergic oIPSCs, neither the amplitude nor the kinetics of eIPSCs were significantly affected after acute mGAT1 inhibition (baseline amplitude: 304 ± 70 pA; 3--4 min after SKF 89976A wash-in: 339 ± 80 pA. Baseline 10--90% rise time: 1.3 ± 0.4 ms; 3--4 min after SKF 89976A wash-in: 1.3 ± 0.4 ms. Baseline decay time constant: 14.8 ± 2.6 ms; 3--4 min after SKF 89976A wash-in: 19.6 ± 4.9 ms; n = 9; p\>0.1 for all, Wilcoxon signed-rank test; [Figure 3A,B](#fig3){ref-type="fig"}), despite a notable increase in holding current during the first few minutes following bath application of SKF 89976A (baseline: −82 ± 16 pA; SKF 89976A: −143 ± 21 pA; n = 9; p\<0.001, Wilcoxon signed-rank test). Moreover, although the amplitude of sIPSCs decreased slightly in SKF 89976A relative to baseline (97 ± 9 vs 83 ± 7 pA, n = 14; p=0.01, Wilcoxon signed-rank test), the frequency and kinetics of sIPSCs remained unchanged (baseline frequency: 2.7 ± 0.5 Hz; 3--4 min after SKF 89976A wash-in: 2.5 ± 0.5 Hz. Baseline 10--90% rise time: 0.9 ± 0.1 ms; 3--4 min after SKF 89976A wash-in: 0.8 ± 0.1 ms. Baseline decay time constant: 6.8 ± 0.4 ms; 3--4 min after SKF 89976A wash-in: 6.4 ± 0.5 ms; p\>0.05 for all, Wilcoxon signed-rank test; [Figure 3C,D](#fig3){ref-type="fig"}). These results are consistent with previous reports in the striatum and hippocampus ([@bib38]; [@bib47]). Thus, our results indicate that prolongation of light-evoked IPSCs by SKF 89976A is specific to dopaminergic synapses and not secondary to increased GABAergic tone. Together, these data reveal that the duration of dopaminergic IPSCs is critically dependent on mGAT1 function and, therefore, strongly support that GABA is the transmitter co-released by DA neurons.10.7554/eLife.01936.008Figure 3.The decay kinetics of electrically-evoked and spontaneous IPSCs are insensitive to mGAT1 inhibition.(**A**) Representative electrically-evoked IPSC before (baseline, black trace) and 3--4 min after (green trace) bath application of SKF 89976A (10 μM). *Inset*, overlay of peak-normalized eIPSCs. (**B**) Plot of individual eIPSC decay time constants before (black) and after (green) SKF 89976A application. Mean (±SEM) shown in red. (**C** and **D**) As in (**A** and **B**) for spontaneous IPSCs. Note that sIPSCs have much faster kinetics compared to eIPSCs.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.008](10.7554/eLife.01936.008)

Mouse midbrain DA neurons do not express GABA synthetic enzymes {#s2-3}
---------------------------------------------------------------

Previous reports indicate that up to 10% of midbrain DA neurons in rat contain detectable levels of mRNA for the 65 kDa isoform of glutamic acid decarboxylase (GAD65) ([@bib33]; [@bib34]). Together with GAD67, these enzymes constitute the major biosynthetic pathway for GABA in the central nervous system ([@bib75]). To determine the fraction of midbrain DA neurons capable of synthesizing (and by extension releasing) GABA in mice, we performed double fluorescence in situ hybridization for *Slc18a2* (*Vmat2*) and *Gad1* or *Gad2* (which encode GAD67 and GAD65, respectively). We focused our analyses to regions highlighted in [Figure 4A](#fig4){ref-type="fig"}, which consist of the SNc and lateral VTA. In agreement with previous findings ([@bib33], [@bib34]), we did not detect significant overlap between *Vmat2* and *Gad1*, as only 4 out of 958 *Vmat2*^+^ neurons (0.4%) showed weak signal for *Gad1* in SNc and lateral VTA ([Figure 4A,B](#fig4){ref-type="fig"}). To our surprise, we were also unable to detect *Gad2* mRNA in these regions ([Figure 4D,E](#fig4){ref-type="fig"}): only 7 out of 1200 *Vmat2*^+^ cells (0.6%) were weakly *Gad2*^+^, despite the presence of numerous brightly-labeled GABAergic neurons in neighboring substantia nigra pars reticulata (SNr) and within the SNc and lateral VTA. We confirmed our ability to detect co-labeling by examining the histaminergic tuberomamillary nucleus (TMN) and dopaminergic A13 cell group ([Figure 4C,F](#fig4){ref-type="fig"}), both of which express GADs ([@bib53]; [@bib25]).10.7554/eLife.01936.009Figure 4.Midbrain DA neurons do not express *Gad1* or *Gad2*.(**A**) Two-color in situ hybridization of *Slc18a2* (*Vmat2*; *top*, red) and *Gad1* (*middle*, green) demonstrates the absence of co-labeled DA neurons (*bottom*) in a coronal section through lateral VTA and SNc (dashed outline). Nuclei are stained blue. SNr, substantia nigra pars reticulata; D, dorsal; V, ventral; M, medial; L, lateral. (**B**) Representative high magnification confocal image of *Slc18a2* (red) and *Gad1* (green) expression in SNc. (**C**) Double fluorescence in situ hybridization for *Slc18a2* and *Gad1* exhibits considerable overlap in the tuberomamillary nucleus (TMN). (**D** and **E**) As in (**A** and **B**) for *Slc18a2* (*Vmat2*) and *Gad2* expression. (**F**) *Slc18a2* and *Gad2* expression co-localize in the A13 dopaminergic cell group.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.009](10.7554/eLife.01936.009)

Levels of mRNA for GAD65 and GAD67 in DA neurons may be below the detection threshold, yet high enough to sustain GABA synthesis. To address this concern, we attempted to directly visualize GAD protein in DA neurons by immunofluorescence using antibodies directed against GAD65/67 and tyrosine hydroxylase (TH) to label catecholaminergic neurons. However, the high density of GABAergic axons converging into the substantia nigra, combined with the low concentration of GADs in cell bodies compared to axon terminals prevented us from clearly identifying DA neurons that expressed GADs (not shown). We instead imaged coronal brain sections from knock-in mice ([@bib79]; [@bib81]) expressing either EGFP or Cre recombinase under transcriptional control of the endogenous promoter for *Gad1* or *Gad2* ([Figure 5](#fig5){ref-type="fig"}). Cre expression was visualized using a sensitive fluorescent reporter allele ([@bib56]) and TH expression was revealed via immunofluorescence. These mice offer the advantage of having bright somatic labeling including, in the case of *Gad2-ires-*Cre mice, of cells with very little transcriptional activity. However, we were unable to detect any DA neuron expressing fluorescent reporter protein driven by either *Gad1* (0 out of 519 TH^+^ neurons) or *Gad2* (0 out of 526 TH^+^ neurons) promoters ([Figure 5A--D](#fig5){ref-type="fig"}). Collectively, these results indicate that midbrain DA neurons in the SNc and lateral VTA of mice do not express the GABA synthetic enzymes GAD65 and GAD67.10.7554/eLife.01936.010Figure 5.DA neurons in SNc/VTA do not express GAD65 or GAD67.(**A**) Low magnification epifluorescence image of a coronal section through the ventral midbrain showing the absence of overlap between tyrosine hydroxylase (TH) immunofluorescence (red) and endogenous EGFP (green) in the SNc and lateral VTA of *Gad1-Egfp* knock-in mice. Blue, nuclear stain. D, dorsal; V, ventral; M, medial; L, lateral. (**B**) Representative high magnification confocal image of SNc in *Gad1-Egfp* mice showing mutually exclusive expression of EFGP and TH, confirming that GAD67 is not expressed in SNc DA neurons. (**C** and **D**) As in (**A** and **B**) for coronal brain sections from *Gad2-ires-Cre* knock-in mice expressing a fluorescence Cre reporter allele (Ai14). TH immunolabeling and Cre reporter fluorescence respectively depicted in red and green for consistency. The absence of overlap indicates that GAD65 is not expressed in DA neurons of the SNc and lateral VTA.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.010](10.7554/eLife.01936.010)

Midbrain DA neurons express GABA transaminase {#s2-4}
---------------------------------------------

Mammalian cells possess alternative means of synthesizing GABA ([@bib74]; [@bib17]; [@bib65]). GABA transaminase is an enzyme expressed at high levels in GABAergic neurons, including in the ventral midbrain that can reversibly convert succinate semialdehyde into GABA, and vice versa ([@bib11]; [@bib68]; [@bib60]). Because succinate semialdehyde is readily oxidized to succinate to sustain energy production as part of the Krebs cycle, GABA transaminase is thought to participate in the degradation of GABA in most cells, not its synthesis ([@bib8]). Nevertheless, we considered the possibility that GABA transaminase might contribute GABA in DA neurons. Double fluorescence in situ hybridization for *Vmat2* and *Abat* (the gene encoding GABA transaminase) revealed strong co-labeling in 701 out of 738 DA neurons (95%) within the SNc and lateral VTA ([Figure 6A,B](#fig6){ref-type="fig"}), indicating that DA neurons express genes involved in GABA metabolism. To test whether DA neurons employ GABA transaminase to synthesize GABA, we incubated slices of striatum in control ACSF or vigabatrin (VGT)---an irreversible inhibitor of GABA transaminase---for at least thirty minutes prior to recording oIPSCs in SPNs. In agreement with prior work ([@bib63]), this manipulation significantly elevated extracellular GABA levels (picrotoxin-sensitive tonic current in SPNs in ACSF: 24 ± 3 pA, n = 11; in VGT: 115 ± 23 pA, n = 12; p\<0.001, Dunn\'s Multiple Comparison Test), confirming the effectiveness of the drug. To minimize differences in light-evoked responses within experiments, we obtained maximal oIPSCs using strong ChR2 stimulation and limited comparisons to SPNs located in similar areas of dorsal striatum in adjacent slices. Under these conditions, we did not detect significant differences in oIPSC amplitude between both groups (ACSF: 1.1 ± 0.3 nA; VGT: 1.4 ± 0.2 nA; n = 14; p=0.3, Wilcoxon signed-rank test; [Figure 6C,D](#fig6){ref-type="fig"}), indicating that GABA transaminase function is not required for GABAergic signaling by DA neurons.10.7554/eLife.01936.011Figure 6.GABA transaminase is not required for GABA release by DA neurons.(**A**) Double fluorescence in situ hybridization for *Slc18a2* (*Vmat2*; red) and *Abat* (green) reveals that midbrain DA neurons overwhelmingly express GABA transaminase. Blue, nuclear stain. D, dorsal; V, ventral; M, medial; L, lateral. (**B**) High magnification confocal image of *Slc18a2* (red) and *Abat* (green) mRNA distribution in SNc. (**C**) Light-evoked IPSCs recorded from SPNs upon strong ChR2 stimulation (1 ms, 5 mW·mm^−2^; blue line) after prolonged incubation in ACSF (black) or vigabatrin (VGT, 100 μM; magenta). (**D**) Plot of mean peak oIPSC amplitude in SPNs recorded in similar regions of dorsal striatum in adjacent slices (depicted by gray lines) incubated in either ACSF (black) or VGT (magenta). Mean (±SEM) values for each group shown in red.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.011](10.7554/eLife.01936.011)

Midbrain DA neurons express plasma membrane GABA transporters {#s2-5}
-------------------------------------------------------------

Our data indicate that inhibitory synaptic transmission from DA neurons does not depend on synthesis of GABA by either GADs or GABA transaminase. In the central nervous system, several synapses rely on neurotransmitter reuptake across the plasma membrane as opposed to de novo synthesis to sustain synaptic transmission ([@bib84]; [@bib24]). It is therefore conceivable that DA neurons inhibit SPNs by releasing GABA they acquire from the extracellular environment. mGAT1 and mGAT4 (encoded by *Slc6a11*) are the two major plasma membrane GABA transporters expressed in the mouse midbrain ([@bib13]; [@bib52]). We therefore performed double fluorescence in situ hybridization for *Vmat2* and *mGat1* or *mGat4* to establish whether either isoform is present in DA neurons ([Figure 7](#fig7){ref-type="fig"}). Surprisingly, we found considerable expression of *mGat1* in 667 out of 748 *Vmat2*^+^ neurons (89%), particularly within the SNc. *mGat4* localized predominantly to glial cells, consistent with previous reports ([@bib13]), although faint labeling above background was also detected in a substantial fraction (80%) of DA neurons in SNc and lateral VTA (568 out of 713 *Vmat2*^+^ neurons).10.7554/eLife.01936.012Figure 7.Midbrain DA neurons express plasma membrane GABA transporters.(**A**) Two color in situ hybridization for *Slc18a2* (*Vmat2*; *top*, red) and *mGat1* (*middle*, green) shows considerable overlap in SNc and lateral VTA (*bottom*). Nuclei are stained blue. D, dorsal; V, ventral; M, medial; L, lateral. (**B**) Representative high magnification confocal image of *Slc18a2* (red) and *mGat1* (green) in SNc confirms that DA neurons express mRNA for mGAT1. (**C**) Same as (**A**) for *Slc18a2* (*top*, red) and *mGat4* (*middle*, green). Note that mGat4 is most strongly expressed in star-shaped glial cells. (**D**) Confocal image through SNc reveals strong expression of *mGat4* mRNA in glial cells and weak labeling in DA neurons.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.012](10.7554/eLife.01936.012)

GAT function is required for dopaminergic IPSCs {#s2-6}
-----------------------------------------------

The expression of mRNA for mGAT1 and mGAT4 in DA neurons raises the possibility that DA neurons acquire GABA not through de novo synthesis, but rather through plasma membrane uptake. Being almost exclusively composed of GABAergic neurons, the striatum represents a rich source of extracellular GABA for dopaminergic terminals ([@bib1]; [@bib47]; [@bib40]; [@bib71]; [@bib18]). Inhibition of mGAT1 for a few minutes does not affect the release of GABA from SNc axons ([Figure 2C](#fig2){ref-type="fig"}), indicating either that this pharmacological manipulation incompletely blocks GABA reuptake, or that it is too short to deplete presynaptic GABA levels. To determine whether uptake of ambient GABA is necessary for sustaining GABAergic transmission by DA neurons, we therefore inhibited both mGAT1 and mGAT4 in striatal slices using a cocktail of SKF 89976A and SNAP-5114 (a mGAT4 antagonist) for at least 30 min prior to examining oIPSCs in SPNs in the continued presence of GAT antagonists. Whereas oIPSCs obtained under control conditions averaged 1.3 ± 0.2 nA in amplitude (n = 15), oIPSCs recorded in adjacent slices with GABA transport chronically blocked were significantly smaller (0.20 ± 0.07 nA, n = 16; p\<0.001 vs ACSF, Dunn\'s Multiple Comparison Test; [Figure 8A,B](#fig8){ref-type="fig"}). Importantly, prolonged exposure to SKF 89976A and SNAP-5114 did not prevent transmitter release non-specifically, as light-evoked dopamine release from SNc axons as well as GABA release from striatopallidal terminals were maintained under these conditions ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Moreover, the small picrotoxin-sensitive oIPSCs that remained exhibited extremely long decay time constants (\>1.5 s), consistent with persistent GABAergic signaling in the absence of plasma membrane reuptake.10.7554/eLife.01936.013Figure 8.Sustained GABAergic signaling from DA neurons requires GAT function.(**A**) Dopaminergic IPSCs evoked by strong ChR2 stimulation (1 ms, 5 mW·mm^−2^; blue line) in slices incubated for at least 30 min in control ACSF (*left*, black), muscimol (0.1 μM; *right*, gray) or a cocktail of mGAT1 and mGAT4 antagonists (10 μM SKF 89976A + 50 μM SNAP-5114, respectively; *middle*, green). Recordings were performed in the continued presence of each drug, in addition to the GABA~B~ receptor antagonist CGP55845 (2--5 μM) and the glutamate receptor blockers NBQX (10 μM) and R-CPP (10 μM). *Inset*, oIPSC in GAT antagonists shown on longer time scale to illustrate slow kinetics. (**B**) Plot of peak oIPSC amplitudes recorded from individual SPNs in adjacent slices after prolonged incubation in ACSF (black), mGAT1 and mGAT4 inhibitors (green) and muscimol (gray). Mean (±SEM) indicated in red. \*p\<0.01 for indicated comparisons, Dunn\'s Multiple Comparison Test. (**C**) Histogram of tonic GABA current (*I*~GABA~) measured in SPNs as the reduction in holding current evoked by bath application of the GABA~A~ receptor antagonist picrotoxin (100 μM) under control conditions (black), or after prolonged incubation in mGAT1 and mGAT4 blockers (10 μM SKF 89976A + 50 μM SNAP-5114; green), muscimol (0.1 μM; gray) or vigabatrin (100 μM; magenta). \*p\<0.01 vs ACSF, Dunn\'s Multiple Comparison Test. Number of recordings indicated in parentheses. (**D**) Plot of consecutive oIPSC amplitudes (normalized to the first light-evoked response) over time under control conditions (ACSF; black; n = 25) and after prolonged incubation in a cocktail of GAT antagonists (10 μM SKF 89976A + 50 μM SNAP-5114; green; n = 11). \*p\<0.001 vs ACSF, Sidak\'s multiple comparison test. (**E**) As in (**D**) for slices supplied with exogenous GABA (100 μM) for 5--10 min before obtaining oIPSCs from SPNs in dorsal striatum (blue; n = 10), and slices supplied with exogenous GABA after prolonged inhibition of GATs with 10 μM SKF 89976A + 50 μM SNAP-5114 (magenta; n = 12). \*p\<0.05 vs ACSF, \#p\<0.005 vs GABA, Tukey\'s multiple comparison test. Control traces in (**D**) and (**E**) are the same as in [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.013](10.7554/eLife.01936.013)10.7554/eLife.01936.014Figure 8---figure supplement 1.Chronic GAT block does not non-specifically affect synaptic transmission at GABAergic and dopaminergic synapses.(**A**) Example traces of light-evoked (1 ms, 5 mW·mm^−2^; blue line) IPSCs recorded from neurons in the external segment of the globus pallidus (GPe; *V*~hold~ = −70 mV) in *Adora2a-Cre*;Ai32 mice, which express ChR2-EYFP in indirect-pathway SPNs. GPe boundaries were identified using the strong EYFP fluorescence of iSPN axonal terminals. Slices were incubated for at least 30 min in ACSF (*left*, black) or in a cocktail of 10 μM SKF 89976A and 50 μM SNAP-5114 (*right*, green). Pre-incubations and recordings were performed in the continued presence of each drug, in addition to CGP55845 (5 μM), NBQX (10 μM) and R-CPP (10 μM). (**B**) Amplitude normalized traces from (**A**) shown on an expanded time scale to reveal the slow decay kinetics of IPSCs in the presence of GAT antagonists. (**C**) The peak amplitude of striatopallidal oIPSCs did not significantly differ (p=0.7; Mann--Whitney test) between slices bathed in ACSF (black; n = 11 GPe neurons) and slices chronically incubated in GAT blockers (green; n = 16 GPe neurons), indicating that this pharmacological manipulation does not inhibit synaptic transmission at 'classical' GABAergic synapses. Mean (±SEM) shown in red. (**D**) Representative traces of light-evoked (1 ms, 5 mW·mm^−2^; blue lines) DA release in the dorsal striatum of *Slc6a3-ires-Cre*;Ai32 measured by carbon-fiber amperometry. Pharmacological conditions are identical to those in (**A**--**C**). Stimulation artifacts are blanked for clarity. (**E**) Peak extracellular DA concentration measured in dorsal striatum slices incubated in ACSF (black; n = 9 slices) or in GAT antagonists (green; n = 14 slices). Population means (±SEM in red) did not differ significantly (p=0.09; Mann--Whitney test).**DOI:** [http://dx.doi.org/10.7554/eLife.01936.014](10.7554/eLife.01936.014)10.7554/eLife.01936.015Figure 8---figure supplement 2.oIPSC rundown is activity dependent.(**A**) The peak amplitude of the first oIPSC recorded in dorsal striatum SPNs within the first 1.5 hr after slicing (black) was comparable to that recorded during the next 1.5 hr (gray), indicating that oIPSCs do not rundown with time in the absence of stimulation. Data in this and subsequent panels represent mean ± SEM. The number of SPNs recorded is indicated in parentheses. (**B**) The time course of synaptic transmission rundown by consecutive light stimuli was similar in the two groups of slices, confirming that recording conditions in the first and second halves of recording sessions are comparable, and that synaptic rundown of DA neuron oIPSCs is dependent on activity. (**C**--**D**) As in (**A**--**B**) for slices chronically incubated for 0.5--1.0 hr (dark green) or 1.1--2.0 hr (light green) in SKF 89976A (10 μM) + SNAP-5114 (50 μM). The effect of GAT inhibition on oIPSC amplitude does not vary with pre-incubation duration (**C**), indicating that our pharmacological manipulation depletes synaptic GABA levels within 30 min. Importantly, stimulation-evoked rundown in GAT blockers is accelerated (contrast panels **B** and **D**), consistent with activity dependent depletion of vesicular GABA when cytoplasmic GABA levels are not replenished by GATs.**DOI:** [http://dx.doi.org/10.7554/eLife.01936.015](10.7554/eLife.01936.015)

Chronic inhibition of GABA reuptake was also accompanied by considerable elevation of ambient GABA in the striatum, as evidenced by a 7.5-fold increase in tonic GABA~A~ receptor-mediated current in SPNs (picrotoxin-evoked tonic current in ACSF: 24 ± 3 pA, n = 11; in GAT antagonists: 182 ± 32 pA, n = 11; p\<0.001, Dunn\'s Multiple Comparison Test; [Figure 8C](#fig8){ref-type="fig"}). This increase in extracellular GABA might account for the reduced amplitude of oIPSCs by promoting the desensitization of GABA~A~ receptors, by shunting synaptic currents, or both. To examine these possibilities, we included an additional experimental condition in which slices were pre-incubated in muscimol before evoking dopaminergic oIPSCs ([Figure 8A,B](#fig8){ref-type="fig"}). Muscimol is a potent synaptic and extrasynaptic GABA~A~ receptor agonist that promotes GABA~A~ receptor desensitization to the same extent as GABA ([@bib62]), but displays minimal affinity for plasma membrane GABA transporters ([@bib43]). The concentration of muscimol was titrated to evoke tonic GABA~A~ receptor-mediated currents similar those that developed upon persistent GAT inhibition (picrotoxin-sensitive tonic current: 212 ± 46 pA, n = 10; p\<0.001 vs ACSF; p\>0.05 vs GAT antagonists, Dunn\'s Multiple Comparison Test; [Figure 8C](#fig8){ref-type="fig"}). Strikingly, this manipulation did not reduce the amplitude of dopaminergic oIPSCs (1.3 ± 0.3 nA, n = 12; p\>0.05 vs ACSF, p\<0.01 vs GAT antagonists, Dunn\'s Multiple Comparison Test; [Figure 8A,B](#fig8){ref-type="fig"}), indicating that the reduction in oIPSC amplitude observed following GAT inhibition is not secondary to elevation of ambient GABAergic tone. In agreement with this conclusion, the amplitude of oIPSCs was not diminished by prolonged treatment with VGT either ([Figure 6C,D](#fig6){ref-type="fig"}), despite significant increases in extracellular GABA (picrotoxin-sensitive tonic current in VGT: 115 ± 23 pA, n = 12; p\<0.01 vs ACSF, p\>0.05 vs GAT antagonists or muscimol, Dunn\'s Multiple Comparison Test; [Figure 8C](#fig8){ref-type="fig"}).

These results collectively indicate that GAT function is necessary for GABAergic transmission from SNc axons. If membrane GABA reuptake is required for supplying GABA for vesicular exocytosis, inhibiting GATs should prevent DA neurons from maintaining GABA release with repeated stimulation. Indeed, chronic inhibition of GATs precipitated the rundown of GABAergic transmission from DA neurons in an activity-dependent manner ([Figure 8D](#fig8){ref-type="fig"}, [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). A second prediction is that elevating extracellular GABA should attenuate synaptic rundown. To test this, we locally applied GABA (100 μM) to the dorsal striatum for 5--10 min prior to recording oIPSCs from SPNs. Following this manipulation, the amplitude of oIPSCs was maintained for several minutes after break-in ([Figure 8E](#fig8){ref-type="fig"}). Importantly, this increase in oIPSC amplitude by exogenous GABA was prevented in slices incubated in GAT antagonists ([Figure 8E](#fig8){ref-type="fig"}). These data therefore provide strong evidence that membrane GABA transporters play an important role in sustaining GABAergic transmission from DA neurons by supplying the neurotransmitter GABA to presynaptic terminals for vesicular loading and exocytosis.

Discussion {#s3}
==========

Despite the importance of midbrain DA neurons, the mechanisms by which they shape the activity of target neurons in the striatum remain poorly understood. In this study, we combined histochemical and electrophysiological approaches to define the cellular and molecular mechanisms that govern GABAergic signaling by DA neurons. Our findings indicate that the vast majority of midbrain DA neurons have the capacity to co-release GABA and identify presynaptic membrane GABA transporters as the likely mechanism employed by DA neurons to acquire GABA for vesicular exocytosis.

Midbrain DA neurons co-release GABA {#s3-1}
-----------------------------------

The chemical identity of a synaptic transmitter is typically established only after several independent observations converge on a plausible candidate. In this case, the transmitter released by midbrain DA neurons (1) functions as a GABA~A~ receptor agonist, (2) serves as a substrate for VGAT ([@bib85]), and (3) is a substrate for mGAT1. Although VGAT can transport GABA, glycine, and β-alanine into synaptic vesicles ([@bib27]; [@bib92]; [@bib46]), glycine does not function as a GABA~A~ receptor agonist, and the low affinity of β-alanine for GABA~A~ receptors would give rise to IPSCs with faster kinetics than the ones we observed ([@bib44]). In addition, mGAT1 is highly selective for GABA ([@bib13]), and applying GABA exogenously helped sustain IPSCs from DA neurons in a GAT-dependent fashion. Although we did not detect GABA synthetic enzymes in DA neurons in our experiments, SNc and VTA neurons display a GABAergic phenotype, as they contain mRNA for GABA transaminase and the membrane GABA transporters mGAT1 and mGAT4. Together, these results strongly suggest that the neurotransmitter released by midbrain DA neurons is GABA. In agreement with this conclusion, a recent electron microscopic study detected GABA in close association with VMAT2-containing synaptic vesicles in dopaminergic terminals within striatum ([@bib77]). Moreover, other dopaminergic neurons in the central nervous system have been reported to contain and/or release GABA, including amacrine cells in the retina ([@bib35]), periglomerular cells in the olfactory bulb ([@bib57]; [@bib14]; [@bib54]), as well as dopaminergic cell groups throughout the brain ([@bib12]; [@bib76]), suggesting that GABA co-release may be a general property of dopaminergic cells.

Midbrain DA neurons sustain inhibitory transmission using plasma membrane uptake of GABA {#s3-2}
----------------------------------------------------------------------------------------

Synaptic transmission requires constant refilling of new and recycled vesicles, which is contingent upon the availability of transmitter in the cytosol. Most GABAergic neurons sustain inhibitory transmission by maintaining high cytosolic concentrations of GABA using de novo synthesis from glutamate by GAD67 and to a lesser extent GAD65 ([@bib5]; [@bib83]; [@bib65]). Given that all cells contain glutamate, an amino acid necessary for the production of proteins, the expression of either GAD67 or GAD65 in conjunction with a vesicular GABA transporter is sufficient to mediate vesicular release of GABA. Previous reports have estimated that up to 10% of DA neurons in the SNc and VTA of rats express mRNA for GAD65 ([@bib33], [@bib34]), suggesting that GABA release may be limited to a subpopulation of DA neurons. We were unable to replicate this observation using two separate approaches, indicating that DA neurons in the SNc and lateral VTA of mice do not rely on de novo synthesis of GABA and have instead adopted other means of obtaining GABA.

Most classical transmitters are transported back into the presynaptic terminal after vesicular release using plasma membrane transporters. This process is important not only for limiting the duration of synaptic currents and preventing extrasynaptic spillover, but also for replenishing presynaptic transmitter levels ([@bib24]; [@bib20]). In fact, several synapses, including monoaminergic ([@bib29]; [@bib10]; [@bib45]; [@bib93]), glycinergic ([@bib30], [@bib31]; [@bib70]; [@bib3]) as well as some GABAergic terminals ([@bib58]; [@bib7]; [@bib26]; [@bib16]; [@bib87]) rely heavily on membrane transporter function to maintain cytosolic transmitter pools available for vesicular loading. Our results show that DA neurons contain mRNA for mGAT1 and mGAT4, indicating that DA neurons might acquire GABA through membrane transport. Indeed, we find that prolonged inhibition of mGAT1 and mGAT4 inhibited GABAergic transmission by DA neurons and precipitated the rundown of oIPSCs, suggesting that DA neurons critically depend on extracellular GABA uptake to maintain cytoplasmic GABA levels and fill synaptic vesicles. By contrast, application of exogenous GABA helped sustain inhibitory transmission from DA neurons. By virtue of the fact that the vast majority of DA neurons in the SNc and lateral VTA contain mRNA for mGATs, our results suggest that GABA co-release is, unlike glutamate co-transmission ([@bib37]), a common feature of these cells in the adult nervous system. The reliance on plasma membrane uptake may partially explain why release of both DA and GABA from these neurons is prone to rundown upon repeated stimulation in brain slices ([@bib72]; [@bib85]; [@bib39]), whereas release of glutamate from dopaminergic neurons or GABA from SPNs (which presumably depend on neurotransmitter synthesis to sustain release) do not suffer from the same shortcoming ([@bib85]; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Nevertheless, these findings provide evidence that the expression of GABA synthetic enzymes is not required to sustain GABAergic transmission, and identify a GABAergic synapse that instead relies entirely on recycling extracellular GABA. Interestingly, a similar mechanism underlies exocytic release of serotonin from dopaminergic neurons ([@bib95]) as well as from glutamatergic thalamocortical neurons during development ([@bib51]).

Implications of GABAergic signaling for striatal function {#s3-3}
---------------------------------------------------------

Although DA neurons in SNc and VTA differ in the inputs they receive and the signals they convey ([@bib59]; [@bib49], [@bib50]; [@bib88]; [@bib69]), we find that both cell populations are capable of co-releasing GABA with DA, pointing to a fundamental property of dopaminergic signaling. Morphological studies of SPNs at the electron microscopic level have revealed that the majority of dopaminergic synapses terminate on the neck of spines that receive excitatory inputs from cortex and thalamus ([@bib90]). Although the actions of DA are not believed to be spatially localized ([@bib4]), this unique synaptic arrangement is indicative of an additional, point-to-point mode of action. An intriguing possibility is that GABA co-release may function to hyperpolarize spines or shunt excitatory cortical and thalamic inputs by activating GABA~A~ receptors. Phasic activation of DA neurons may thereby dampen ongoing cortical and thalamic drive onto SPNs to limit DA receptor-mediated plastic changes to synaptic inputs most strongly activated by salient or rewarding stimuli. In addition, the mechanism adopted by DA neurons to obtain GABA may confer these cells the flexibility to dynamically and locally control GABAergic transmission across their extensive axonal arbors. For instance, VTA neurons projecting to NAc and medial prefrontal cortex may only co-release GABA in the former, where extracellular GABA levels are high compared to cortex ([@bib23]; [@bib89]). Alternatively, phasic and chronic changes in mGAT function or extracellular GABA levels resulting from synaptic activity, drugs or disease may alter the amplitude and kinetics of GABAergic currents arising from midbrain dopamine neurons. A greater understanding of the relative effects of DA and GABA on the activity of striatal circuits will help reveal how DA neurons contribute to behavior in health and disease.

Materials and methods {#s4}
=====================

Experimental subjects and stereotaxic surgery {#s4-1}
---------------------------------------------

All experimental manipulations were performed in accordance with protocols approved by the Harvard Standing Committee on Animal Care following guidelines described in the US National Institutes of Health *Guide for the Care and Use of Laboratory Animals*. All mice were group-housed and maintained on a 12-hr light cycle with *ad libitum* access to food and water. *Slc6a3-ires-Cre* knock-in mice expressing Cre recombinase in DA neurons ([@bib6]) were obtained from Jackson Labs (Bar Harbor, ME; stock \# 006660). These mice were crossed with *Drd2-Egfp* (GENSAT, founder line S118) or *Drd1a-tdTomato* (stock \# 016204; Jackson Labs) BAC transgenic mice to permit distinction between direct- and indirect-pathway SPNs ([@bib32]; [@bib2]). To genetically target indirect pathway SPNs, *Adora2a-Cre* BAC transgenic mice (GENSAT, founder line KG139) were used. For stereotaxic viral injections, postnatal day 18--25 mice were anesthetized with isoflurane, placed in a small animal stereotaxic frame (David Kopf Instruments, Tujunga, CA) and injected with 1 μl of an adeno-associated virus (∼10^12^ genome copies per ml; UNC Vector Core Facility, Chapel Hill, NC) encoding Cre-dependent ChR2 (AAV2/8.EF1α.DIO.hChR2(H134R)-mCherry or AAV2/8.EF1α.DIO.hChR2(H134R)-EYFP), as described previously ([@bib85]). Injection coordinates were 0.8 mm anterior from Lambda, 1.3 mm lateral and 4.4 mm below pia for SNc, and 0.8 mm anterior from Lambda, 0.6 mm lateral and 4.4 mm below pia for VTA. Alternatively, ChR2(H134R)-EYFP was expressed genetically in Cre-containing cells by crossing *Slc6a3-ires-Cre*;*Drd2-Egfp* or *Slc6a3-ires-Cre*;*Drd1a-tdTomato* mice with Ai32 mice (stock \# 012569; Jackson Labs) ([@bib55]). The knock-in lines used in [Figure 5](#fig5){ref-type="fig"} include *Gad1-Egfp* ([@bib79]) and *Gad2-ires-Cre* mice ([@bib81]). The latter were crossed with mice bearing a Cre-dependent tdTomato reporter transgene (Ai14; stock \# 007914; Jackson Labs) to reveal the distribution of Cre^+^ cells ([@bib56]). Mice were maintained on a C57BL/6 background. Only mice heterozygous for all transgenes were used for experiments.

Immunocytochemistry and in situ hybridization {#s4-2}
---------------------------------------------

Mice were anesthetized with isoflurane and transcardially perfused with phosphate buffered saline followed by 4% (wt/vol) paraformaldehyde in 0.1 M sodium phosphate buffer. 50-micrometer coronal brain sections were subject to immunohistochemical staining for tyrosine hydroxylase (AB152; 1:2000; Millipore, Billerica, MA), as described previously ([@bib85]). Endogenous tdTomato and EGFP fluorescence were not immuno-enhanced. Double fluorescence in situ hybridization was performed using a tyramide signal amplification method according to the manufacturer\'s instructions (NEL753001KT; PerkinElmer, Waltham, MA), as previously described ([@bib48]). Briefly, brains from 4-week old mice were dissected and immediately frozen in liquid nitrogen. They were then cut in 25-μm-thick sections with a cryostat (Leica, Buffalo Grove, IL), postfixed in 4% PFA, acetylated in 1% triethanolamine and 0.25% acetic anhydride, dehydrated serially in ethanol, bleached in 3% hydrogen peroxide diluted in methanol, prehybridized, and hybridized at 65°C using the following anti-sense probes provided by the Allen Institute for Brain Science (riboprobe ID specified in parentheses): *Gad1* (RP_040324_01_F01), *Gad2* (RP_071018_02_B07), *Vmat2* (RP_071218_02_B08), mouse *Gat1* (RP_071204_04_H01), mouse *Gat4* (RP_050428_04_D04), and *Abat* (RP_050301_02_C02). For in vitro transcription, each cDNA was cloned out from a mouse brain cDNA library using the primer sets suggested in the in situ hybridization data portal from the Allen Institute for Brain Science. Two fluorescein- or digoxigenin-labeled riboprobes generated by an in vitro transcription method (Promega, Madison, WI) were hybridized simultaneously and stained by fluorescein or Cy3 chromogens, respectively. After staining, sections were mounted with Prolong Gold antifade reagent with DAPI nuclear stain (Life Technologies, Grand Island, NY).

Slice electrophysiology {#s4-3}
-----------------------

Acute brain slices and whole-cell voltage-clamp recordings from identified SPNs were obtained using standard methods, as described previously ([@bib85]). Briefly, mice (49--178 days old; median = 107 days) were anesthetized and perfused with ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM) 125 NaCl, 2.5 KCl, 25 NaHCO~3~, 2 CaCl~2~, 1 MgCl~2~, 1.25 NaH~2~PO~4~ and 11 glucose (295 mOsm·kg^−1^). Parasagittal slices of striatum (275-μm thick) were subsequently obtained in cold choline-based cutting solution (in mM: 110 choline chloride, 25 NaHCO~3~, 2.5 KCl, 7 MgCl~2~, 0.5 CaCl~2~, 1.25 NaH~2~PO~4~, 25 glucose, 11.6 ascorbic acid, and 3.1 pyruvic acid). Following 15 min recovery in ACSF at 34°C, slices were kept at room temperature (20--22°C) until use. All solutions were constantly bubbled with 95% O~2~/5% CO~2~. Whole-cell voltage-clamp recordings were established from direct- and indirect-pathway SPNs in dorsal or ventral striatum resting 18--75 μm below the slice surface (median: 40 μm) in ACSF warmed to 32--34°C. Direct-pathway SPNs were identified as tdTomato^+^ cells in *Drd1a-tdTomato* mice or EGFP^--^cells in *Drd2-EGFP* mice, and indirect-pathway SPNs as tdTomato^−^or EGFP^+^ cells in *Drd1a-tdTomato* and *Drd2-EGFP* mice, respectively. Patch pipettes (2--4 MΩ) were filled with (in mM) 125 CsCl, 10 TEA-Cl, 10 HEPES, 0.1 Cs-EGTA, 3.3 QX-314 (Cl^−^salt), 4 Mg-ATP, 0.3 Na-GTP, 8 Na~2~-Phosphocreatine (pH 7.3 adjusted with CsOH; 295 mOsm·kg^−1^). The recording perfusate always contained NBQX (10 μM) and R-CPP (10 μM) to block AMPA and NMDA receptor-mediated inward currents, respectively, as well as CGP55845 (2--5 μM) to prevent GABA~B~ receptor-evoked pre- and post-synaptic modulation. For some experiments ([Figures 6 and 8](#fig6 fig8){ref-type="fig"}, [Figure 8---figure supplements 1 and 2](#fig8s1 fig8s2){ref-type="fig"}), slices were incubated for at least 30 min (and up to two hours) in ACSF containing CGP55845 (2--5 μM) in addition to vigabatrin (100 μM), muscimol (0.1 μM), or SKF 89976A (10 μM) + SNAP-5114 (50 μM) to allow for the depletion of cytosolic GABA levels and synaptic vesicles containing GABA, and to control for the effects of chronically elevated GABAergic signaling. In these cases, drugs continued to be present in the recording chamber for the duration of the experiment. For [Figure 8E](#fig8){ref-type="fig"}, GABA (100 μM, in ACSF containing either 5 μM CGP55845 or 5 μM CGP55845 + 10 μM SKF 89976A + 50 μM SNAP-5114) was locally applied to the slice via a gravity-fed 250-μm-wide flow pipe for 5--10 min prior to recording. For all voltage-clamp experiments, errors due to the voltage drop across the series resistance (\<20 MΩ) were left uncompensated. Membrane potentials were corrected for a ∼5-mV liquid junction potential. Under these conditions, GABA~A~ receptor-mediated currents appeared inward when SPNs were held at negative membrane potentials (*V*~hold~ = −70 mV). To activate ChR2-expressing fibers, light from a 473-nm laser (Optoengine, Midvale, UT) was focused on the back aperture of the microscope objective to produce wide-field illumination of the recorded cell. Brief pulses of light (1-ms duration; 5 mW·mm^−2^ under the objective for maximal stimulation, 0.3--2 mW·mm^−2^, for sub-maximal stimulation) were delivered at the recording site at 30 s intervals under control of the acquisition software. Epifluorescence illumination was used sparingly to minimize ChR2 activation prior to recording. eIPSCs were evoked using constant-current pulses (0.1 ms, 7--90 μA) delivered every 15 s through a bipolar tungsten stimulating electrodes positioned within striatum, 100--200 μm away from the recorded cell. Constant-potential amperometry was performed as before ([@bib85]) using commercial glass-encased carbon-fiber microelectrodes (Carbostar-1, Kation Scientific, Minneapolis, MN) placed within dorsal striatum slices and held at 600 mV. All recordings were obtained within 4 hr of slicing. All pharmacological agents were obtained from Tocris (Minneapolis, MN).

Data acquisition and analysis {#s4-4}
-----------------------------

Brain sections processed for in situ hybridization or immunofluorescence were imaged with an Olympus VS110 slide-scanning microscope. High-resolution images of regions of interest were subsequently acquired with a Zeiss LSM 510 META confocal microscope (Harvard NeuroDiscovery Center). Individual imaging planes were overlaid and quantified for colocalization in ImageJ (NIH) and thresholded for display in Photoshop (Adobe). Confocal images in figures represent maximum intensity projections of 3-µm confocal stacks. Membrane currents were amplified and low-pass filtered at 3 kHz using a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), digitized at 10 kHz and acquired using National Instruments acquisition boards and a custom version of ScanImage ([@bib66]; available upon request or from <https://openwiki.janelia.org/wiki/display/ephus/ScanImage>) written in MATLAB (Mathworks). Electrophysiology data were analyzed offline using Igor Pro (Wavemetrics, Natick, MA). In figures, voltage-clamp traces represent the averaged waveform of 3--5 consecutive acquisitions. Averaged waveforms were used to obtain current latency, peak amplitude, 10--90% rise time and decay time constant. The latter was estimated by measuring the time elapsed from the peak of the IPSC to 1/*e* (36.8%) of the peak amplitude. Detection threshold for sIPSCs was set at 40 pA to facilitate event detection in the presence of large and noisy tonic GABA currents. For pharmacological analyses in [Figures 2 and 3](#fig2 fig3){ref-type="fig"}, the peak amplitude of IPSCs measured 3--4 min following the onset of drug perfusion were averaged, normalized to baseline averages obtained immediately prior to drug application and compared statistically to values obtained at corresponding times in control preparations bathed in ACSF. Data (reported in text and figures as mean ± SEM) were compared using Prism 6 (GraphPad, La Jolla, CA) with the following non-parametric statistical tests (as indicated in the text): Mann--Whitney for group comparisons, Wilcoxon signed-rank for paired comparisons, and Kruskal--Wallis analysis of variance (ANOVA) followed by Dunn\'s Multiple Comparison Test for multiple group comparisons. In experiments characterizing the time course of synaptic transmission rundown, two-way ANOVAs were used followed by the Sidak\'s and Tukey\'s multiple comparison tests for comparisons between two and more conditions, respectively. p values smaller than 0.05 were considered statistically significant. N values represent the number of recorded cells. For most experiments, a single cell was recorded from in each slice, with each animal contributing fewer than five recordings to individual data sets.
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Thank you for sending your work entitled "Midbrain dopamine neurons sustain inhibitory transmission using plasma membrane uptake of GABA, not synthesis" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, one of whom is a member of our Board of Reviewing Editors. The Reviewing editor and the other reviewers discussed their comments before reaching this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This relatively straightforward report follows up on prior work of these authors examining the corelease of GABA from "dopamine" neurons. In this report they extend their studies from the nigrostriatal pathway to the mesolimbic pathway. Interestingly GABA is supplied not by synthetic enzymes in the neurons, but rather by expression of membrane GABA transporters. As previously shown, vesicular uptake of GABA can be performed by the vesicular monamine transporter VMAT2. The questions addressed in this manuscript are whether such corelease occurs in the mesolimbic pathway and whether the agonist is GABA or a related analog.

The authors nicely demonstrate in [Figure 1](#fig1){ref-type="fig"} that VTA inputs to NAc have similar properties with respect to GABA corelease as the previously demonstrated SNc inputs to dorsal striatum. The majority of the figures then focus on the identity and source of GABA in the VTA-NAc pathway. These experiments are carefully conducted and well presented and convincingly demonstrate that GABA is the principal agonist and that the main source is membrane uptake rather than intracellular synthesis. Although these results are somewhat predictable from prior studies and could be further extended, the results are important in understanding the rather novel, albeit still somewhat mysterious, role of a fast-acting transmitter in midbrain dopamine neurons, and thus should be of interest to a broad community of neuroscientists. The substantial comments of the 3 reviewers are numbered below.

1\) These data make several specific, testable predictions that would enhance the strength of the main interpretation. For example, increasing extracellular GABA should increase the amplitude of DA-IPSCs through an mGAT-dependent mechanism. Does bath application of GABA, or perhaps extracellular GABA uncaging, increase DA-IPSCs? And is this effect blocked by the acute presence of mGAT blockers during said GABA application? [@bib87] (cited) showed that GAT activity can rescue transmission in conventional GABAergic synapses when GABA is bath applied in the presence of gabazine. This experiment would reveal the timecourse over which DA neurons take up GABA from the extracellular space and package it into synaptic vesicles, and it would be important to contrast the timecourse of the authors\' novel mechanism with that of enzymatic synthesis at more traditional GABA synapses. This experiment would enhance also the claim that GAT supplies the GABA used for synaptic vesicles.

2\) A second prediction is that rundown of transmission induced by SKF should be activity dependent. I found it confusing at first that [Figure 2](#fig2){ref-type="fig"} shows little effect of SKF on IPSC amplitude and [Figure 7](#fig7){ref-type="fig"} shows a large effect, and I am sure readers will also be caught off guard. The difference is that with time the synapses in SKF are depleted of GABA. Therefore if the synapses were stimulated one might expect to accelerate the process, confirming that it reflects depletion of vesicular GABA rather than a side effect of the drug.

3\) The authors deal with a number of potential confounding factors such as the increased tonic GABA currents produced by GABA transporter inhibition, showing that this does not affect the kinetics of quantal GABA events from sources other than dopamine neurons. On the other hand, it is remarkable that the inhibitor does not affect the kinetics of these other events -- is it so selective for GABA release from dopamine neurons because the transporter is only expressed on those terminals? It would be helpful if the authors could address this surprising result -- previous work has indicated expression of GAT-1 by SPNs and an effect of a different inhibitor (NO-711) on amplitude and decay time of events evoked by local depolarization ([@bib47]).

4\) Treatment with GAT-1 inhibitor for longer times effectively eliminates the GABA release by dopamine neurons, as anticipated if it depends on the GABA taken up from other cells. However, it is also possible that dopamine neurons make GABA themselves, and the main argument used here against this is the apparent lack of expression by a variety of criteria. Although these seem reasonable, other work cited by the authors in a different context ([@bib77]) along with other work they do cite suggests expression of GAD by a subset of dopamine neurons. Rather than rely on the anatomy, it would help greatly to demonstrate that inactivation of GAD specifically in dopamine neurons does not eliminate the dopaminergic IPSCs. This might require a substantial amount of work that would lie outside the scope of this manuscript (for example a double knockout of both isoforms that is conditional and may not even be available), but it would certainly be helpful. However, showing that expression of a GAD isoform in dopamine neurons makes the dopaminergic IPSCs resistant to inhibition of GAT-1 would be considerably simpler.

5\) The authors also suggest that GABA corelease involves both mesostriatal and mesolimbic projections, in contrast to the apparent corelease of glutamate by a subset of VTA neurons. However, [@bib77] also showed that only ∼10 % of striatal terminals apparently contain GABA, raising the question whether the dopaminergic IPSCs derive from a subset of both populations, or all of them. It would be great if the authors could address this point, and one way might be to determine whether GAT-1 inhibition influences dopamine release measured by voltammetry-GABA corelease by many terminals should have some effect on total dopamine release, but involvement of only a subset would produce minimal if any effect. This would also help to address one important functional outcome of corelease that has not yet been examined.

10.7554/eLife.01936.017

Author response

We are thankful for the reviewers' prompt evaluation of our manuscript and for their valuable comments and suggestions. We are delighted that our work was reviewed favorably and described as "straightforward", "carefully conducted" and "well-presented". We agree with the reviewers that the results described in our study are an important and necessary first step to elucidate the mysterious role of fast-acting neurotransmission from midbrain dopamine neurons. However, we take exception with the notion that the principal findings of this study were in any way predictable from prior work. Although our initial study ([@bib85]) pointed to GABA as being the transmitter released by dopamine neurons, we acknowledged that other molecules might perform similar functions, and remained agnostic as to the identity of the co-released transmitter as we initiated and carried out the present study. This was particularly true when we failed to detect GABA synthetic enzymes in midbrain dopamine neurons. Moreover, we are not aware of any prior evidence that might have predicted that midbrain dopamine neurons acquire GABA through membrane uptake as opposed to intracellular synthesis.

Please find below our response to each of the reviewer's comments. We hope the reviewers will find our revised manuscript improved and suitable for publication.

*1) These data make several specific, testable predictions that would enhance the strength of the main interpretation. For example, increasing extracellular GABA should increase the amplitude of DA-IPSCs through an mGAT-dependent mechanism. Does bath application of GABA, or perhaps extracellular GABA uncaging, increase DA-IPSCs? And is this effect blocked by the acute presence of mGAT blockers during said GABA application?* [@bib87] *(cited) showed that GAT activity can rescue transmission in conventional GABAergic synapses when GABA is bath applied in the presence of gabazine. This experiment would reveal the timecourse over which DA neurons take up GABA from the extracellular space and package it into synaptic vesicles, and it would be important to contrast the timecourse of the authors\' novel mechanism with that of enzymatic synthesis at more traditional GABA synapses. This experiment would enhance also the claim that GAT supplies the GABA used for synaptic vesicles*.

We performed the experiment suggested by the reviewers, in which we show that bath application of GABA increases the amplitude of IPSCs evoked by dopaminergic neuron stimulation in a GAT-dependent manner. These data are consistent with the claim that GABA is the transmitter released, and that it is supplied by GATs for vesicular release. These results are now shown in [Figure 8](#fig8){ref-type="fig"}, and discussed in the text.

Technical limitations unfortunately prevented us from performing the second series of experiments, which would have allowed us to contrast the time course of GABA uptake and vesicular filling in dopamine neurons with that of 'classical' GABAergic synapses that depend on GABA synthesis. The studies by [@bib87] were performed in culture and the authors benefited from stable IPSC amplitudes, as well as the ability to rapidly apply and remove extracellular solutions containing GABA, gabazine and SKF89976A. In our experiments in which, the axons are, by necessity, severed from the cell bodies, the amplitude of dopaminergic IPSCs runs down considerably with time (see discussion below and [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}) and complete washout of gabazine is slow (tens of minutes) and variable in duration, effectively preventing us from carrying out similar analyses. It is also unclear that we would be able to assign differences in time course to enzymatic synthesis vs. membrane uptake, as classical GABAergic synapses and this one also rely on distinct vesicular transporters (VGAT and VMAT2, respectively), which most certainly differ in transport kinetics.

*2) A second prediction is that rundown of transmission induced by SKF should be activity dependent. I found it confusing at first that* [*Figure 2*](#fig2){ref-type="fig"} *shows little effect of SKF on IPSC amplitude and* [*Figure 7*](#fig7){ref-type="fig"} *shows a large effect, and I am sure readers will also be caught off guard. The difference is that with time the synapses in SKF are depleted of GABA. Therefore if the synapses were stimulated one might expect to accelerate the process, confirming that it reflects depletion of vesicular GABA rather than a side effect of the drug*.

We apologize for the confusion and thank the reviewers for pointing out the need to clarify the description of our experimental manipulations. As the reviewers indicate, the major difference between [Figures 2 and 7](#fig2 fig7){ref-type="fig"} is the duration of drug application. [Figure 2](#fig2){ref-type="fig"} describes the acute effects of SKF89976A within the first few minutes of bath application. Under these conditions, we did not observe any effect of SKF89976A (or SKF89976A + SNAP-5114; See [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}) on the amplitude of oIPSCs. This indicates that blocking membrane GABA reuptake does not immediately interfere with the ability of dopaminergic terminals to release GABA, presumably because synaptic vesicles are already filled and cytoplasmic GABA levels have not yet been depleted. In [Figure 8](#fig8){ref-type="fig"}, slices were incubated for thirty or more minutes in SKF89976A + SNAP-5114 to allow for depletion of cytoplasmic (and by extension vesicular) GABA in dopaminergic synapses. We have modified the text to stress this distinction.

Following the reviewers' suggestion, we now provide evidence in [Figure 8D](#fig8){ref-type="fig"} that the rundown process is accelerated following chronic GAT blockade, and in [Figure 8--figure supplements 1 and 2](#fig8s1 fig8s2){ref-type="fig"} that the effect of this manipulation on oIPSC amplitude does not reflect a side effect of the drug. Specifically, we show that, in addition to reducing the amplitude of optogenetically-evoked IPSCs, prolonged GAT blockade significantly accelerates rundown of GABAergic transmission. We did not detect differences in either the amplitude of IPSCs or the time course of rundown between slices that were incubated in SKF89976A + SNAP-5114 for less than one hour or between one and two hours, indicating that rundown is activity dependent. Importantly, preventing membrane GABA uptake for thirty minutes or longer does not prevent synaptic release of dopamine from nigrostriatal axons or GABA from striatopallidal terminals indicating that SKF89976A and SNAP-5114 do not impair synaptic transmission non-specifically. These results are therefore consistent with the hypothesis that chronic block of membrane GABA reuptake selectively inhibit GABAergic transmission at dopaminergic synapses by depleting cytosolic GABA levels.

*3) The authors deal with a number of potential confounding factors such as the increased tonic GABA currents produced by GABA transporter inhibition, showing that this does not affect the kinetics of quantal GABA events from sources other than dopamine neurons. On the other hand, it is remarkable that the inhibitor does not affect the kinetics of these other events -- is it so selective for GABA release from dopamine neurons because the transporter is only expressed on those terminals? It would be helpful if the authors could address this surprising result -- previous work has indicated expression of GAT-1 by SPNs and an effect of a different inhibitor (NO-711) on amplitude and decay time of events evoked by local depolarization (*[@bib47]*)*.

The different sensitivity of IPSCs originating from dopamine neurons vs. 'classical' GABAergic neurons to SKF89976A is indeed remarkable, pointing to fundamental structural and/or biochemical differences between both synapses. It is unlikely that selective expression of mGAT1 in dopamine neurons fully accounts for this difference, as mGAT1 is expressed widely throughout the brain, including in the striatum. However, it is possible that dopaminergic synapses rely exclusively on mGAT1 for membrane GABA transport, whereas classical GABAergic synapses may utilize other transporters in the presence of SKF89976A, such as mGAT4. Indeed, the tonic GABA current evoked by acute bath application of SKF89976A and SNAP-5114 (a mGAT4 antagonist) is more than twice that of SKF89976A alone (picrotoxin-evoked current in SKF89976A: 90 ± 9 pA, n = 15 SPNs; in SKF89976A+SNAP-5114: 198 ± 29 pA, n = 10 SPNs; P = 0.005, Mann Whitney test). Additional factors may contribute to differences in the sensitivity of IPSC kinetics to GAT blockers, including GABAA receptor subunit composition ([@bib1]), GABAA receptor desensitization (Overstreet et al. 2000; [@bib63]), stimulation strength ([@bib38]) and synapse density ([@bib64]), amongst others.

The reviewers correctly note that another group ([@bib47]) previously reported changes in the amplitude and kinetics of electrically-evoked IPSCs in striatum following mGAT1 inhibition. In that study, the observed decrease in IPSC amplitude was attributed to presynaptic GABAB receptors, which were pharmacologically blocked in our experiments. The effect on IPSC kinetics consisted of a slight increase (13 %) in the time taken for the current to decay to 10 % of the peak amplitude in P12-14 slices recorded at ambient temperature. It is unclear whether a significant effect would have been detected using more classical measures of decay time, or if this effect would be maintained in older animals and at elevated temperatures. Importantly, GABAergic IPSCs are particularly heterogeneous in their sensitivity to GAT blockade, which is strongly influenced by experimental conditions ([@bib38]; [@bib64]).

*4) Treatment with GAT-1 inhibitor for longer times effectively eliminates the GABA release by dopamine neurons, as anticipated if it depends on the GABA taken up from other cells. However, it is also possible that dopamine neurons make GABA themselves, and the main argument used here against this is the apparent lack of expression by a variety of criteria. Although these seem reasonable, other work cited by the authors in a different context (*[@bib77]*) along with other work they do cite suggests expression of GAD by a subset of dopamine neurons. Rather than rely on the anatomy, it would help greatly to demonstrate that inactivation of GAD specifically in dopamine neurons does not eliminate the dopaminergic IPSCs. This might require a substantial amount of work that would lie outside the scope of this manuscript (for example a double knockout of both isoforms that is conditional and may not even be available), but it would certainly be helpful. However, showing that expression of a GAD isoform in dopamine neurons makes the dopaminergic IPSCs resistant to inhibition of GAT-1 would be considerably simpler*.

[@bib77] used immunogold EM to localize GABA within TH^+^ and VMAT2^+^ terminals in the striatum of mice and rats, but did not examine the distribution of GADs. We only know of two studies having directly investigated whether SNc and VTA dopamine neurons express GADs ([@bib33], [@bib34]). These studies reported that while 6-10 % of midbrain dopamine neurons in rat contain detectable levels of mRNA for GAD65, their soma is immuno- negative for GABA and GAD65, indicating that SNc/VTA neurons may not be able to synthetize GABA. Our in situ hybridization data in wildtype mice, in combination with our immuno-histochemical analyses in transgenic reporter animals are consistent with this conclusion, as both approaches convincingly showed that dopamine neurons in the SNc and lateral VTA do not express the GABA synthetic enzymes GAD65 or GAD67.

In the revised manuscript, we provide additional functional evidence for GATs being necessary for GABAergic transmission in dopaminergic neurons, and include control experiments showing that chronic inhibition of GATs does not non-specifically impair vesicular release from midbrain dopamine neurons, or GABA release from a classical GABAergic synapse. Thus, we are currently unaware of any compelling anatomical or functional evidence in favor of midbrain dopamine neurons directly synthetizing GABA for release using GADs.

Global and conditional knockout mice for GAD65 and GAD67 exist, respectively (Asada et al*.* 1996; Obata et al*.* 2008), but we currently do not have access to them. Carrying out the suggested GAD knockout experiment would require a substantial amount of work (breeding mice harboring 5 transgenic alleles: Gad1^f/f^; Gad2^-/-^; DatIRES-Cre/wt) that is not motivated by prior or current evidence for GAD expression in midbrain dopamine neurons. We therefore agree with the reviewers that this experiment is beyond the scope of this manuscript.

Although the suggested gain-of-function experiment is considerably simpler, it too requires experimental tools (viral vectors encoding GADs) that are currently not at our disposal and would take several months to generate and characterize. We agree that it would nicely demonstrate that the inhibition of oIPSCs by GAT antagonists does not stem from unintended effects of these drugs on synaptic vesicle exocytosis or GABA synthesis by GADs. However, this experiment would, by itself, offer little additional insight as to the molecular mechanism normally responsible for providing GABA to midbrain dopamine neurons. Control experiments are now provided in [Figure 8--figure supplement 1](#fig8s1){ref-type="fig"}, which demonstrate that blockade of GATs has no effect on dopamine release from SNc axons and no effect on GABA release from striatopallidal terminals. In light of these findings, we hope that the reviewers agree that the results of the proposed gain-of-function experiment would not affect our conclusions, and that this experiment is therefore not essential to substantiate the claim that GATs are necessary for sustaining GABAergic transmission in midbrain dopamine neurons.

*5) The authors also suggest that GABA corelease involves both mesostriatal and mesolimbic projections, in contrast to the apparent corelease of glutamate by a subset of VTA neurons. However,* [@bib77] *also showed that only ∼10 % of striatal terminals apparently contain GABA, raising the question whether the dopaminergic IPSCs derive from a subset of both populations, or all of them. It would be great if the authors could address this point, and one way might be to determine whether GAT-1 inhibition influences dopamine release measured by voltammetry-GABA corelease by many terminals should have some effect on total dopamine release, but involvement of only a subset would produce minimal if any effect. This would also help to address one important functional outcome of corelease that has not yet been examined*.

The study by [@bib77] is remarkable in that it convincingly reveals the existence dopaminergic terminals in the striatum of mice and rats that contain a high density of immunogold particles for GABA. However, immunogold EM is a challenging technique that severely underlabels molecules of interest, and therefore does not easily lend itself to absolute measures of expression: the fact that 10 % of dopaminergic terminals contained enough immunogold particles to qualify as being GABAergic cannot be interpreted to mean that 90 % do not contain GABA. Instead, their data indicate 1) that dopaminergic terminals contain the neurotransmitter GABA, 2) that GABA is present in or near VMAT^+^ synaptic vesicles, and 3) that the concentration of GABA is large enough to be detected in a sizeable fraction of dopaminergic terminals.

Nevertheless, the question raised by the reviewers is important, as establishing whether GABA co-release is common to all midbrain dopamine neurons or a unique feature of a subset of cells is essential to determine its functional relevance. It should be noted that regardless of the molecular mechanisms engaged or the fraction of midbrain dopamine neurons implicated, GABA co-transmission may be a general feature of monoaminergic neurons, as opposed to an exception, suggesting an important role for dopamine-GABA co-transmission (see references in this manuscript and [@bib85]).

Determining whether optogenetically-evoked GABAergic currents arise from release in all terminals, or from a fraction of terminals is challenging, and it is unclear how the suggested electrochemical experiment would address this point. We currently do not have evidence pointing to a GABAergic modulation of dopamine exocytosis (measured by amperometry): light-evoked dopamine release is unaffected by inhibition of GABAA receptors ([@bib85]) or by activation of GABAB receptors with baclofen (5 μM; unpublished observation). Moreover, we now provide amperometry data showing that dopamine release is not changed after chronic inhibition of GAT ([Figure 8--figure supplement 1](#fig8s1){ref-type="fig"}), indicating that neither buildup of extracellular GABA in the slice, nor depletion of cytosolic GABA in dopaminergic terminals significantly affect dopamine release.

The suggestion that GABA co-release in the striatum may apply to all midbrain dopamine neurons (as opposed to a subset of SNc and VTA neurons) is based on several observations. First, oIPSCs are large and present in every SPN studied to date, as opposed to glutamatergic events, which are significantly smaller in amplitude and only observed in a fraction SPNs ([@bib85]). Second, minimum stimulation experiments suggest that oIPSCs in SPNs represent compound responses to numerous small-amplitude GABAergic inputs as opposed to a few large ones ([@bib85]). Third, mGat1 mRNA was detected in the vast majority of midbrain dopamine neurons, suggesting that most cells have the ability to take up GABA from the extracellular space in GABA-rich brain regions such as the striatum. Although not definitive, these experiments strongly suggest that GABA co-release is a general feature of most dopaminergic terminals in the striatum.
